Report looks at cost to health system of brand name drug tactic

by on

Report looks at cost to health system of brand name drug tactic
tjordan_drupal
Sep 14, 2020

A new study demonstrates the cost to the U.S. health care system from an anti-competitive tactic known as “product hopping,” which involves a brand name drug company moving patients to a new reformulated version of a drug when an existing drug’s exclusivity is close to expiring.

The study by Alex Brill of Matrix Global Advisors, commissioned by the Coalition for Affordable Prescription Drugs, finds that product hopping for the brand drugs Prilosec, TriCor, Suboxone, Doryx and Namenda cost the U.S. health care system $4.7 billion annually.

Headline

Report looks at cost to health system of brand name drug tactic
tjordan_drupal
Sep 14, 2020

A new study demonstrates the cost to the U.S. health care system from an anti-competitive tactic known as “product hopping,” which involves a brand name drug company moving patients to a new reformulated version of a drug when an existing drug’s exclusivity is close to expiring.

The study by Alex Brill of Matrix Global Advisors, commissioned by the Coalition for Affordable Prescription Drugs, finds that product hopping for the brand drugs Prilosec, TriCor, Suboxone, Doryx and Namenda cost the U.S. health care system $4.7 billion annually.

Drug Price Transparency

Headline

VA:F [1.9.7_1111]
Rating: 0.0/10 (0 votes cast)
VA:F [1.9.7_1111]
Rating: 0 (from 0 votes)

Leave a Comment

Previous post:

Next post: